Latest News
& Press Releases

Clover’s SCB-2019 showed a robust immune response to the Omicron BA.5 sub-variant, while BrainsWay, TikoMed and more provide updates on their businesses and pipelines.

The University of Michigan and the University of South Florida have filed a lawsuit against Novartis, alleging the company’s cardiac drug, Entresto, infringes a cocrystal patent held by both universities.

Mesoblast fell short of analyst forecasts this week, and money is pouring into glaucoma, medical devices for heart disease and chronic endocrine conditions.

In the wake of the COVID-19 pandemic, several Western nations are investing heavily in rapidly developing drugs to treat populations when new pandemics emerge.

A 2022 Industry Snapshot from MassBio shows there continues to be significant growth across the Massachusetts ecosystem, driven by billions of dollars in venture capital investments.

New Initiative to create resources to increase engagement in crystallography and structural science

The life science field offers a wealth of opportunities, even for those working outside of the field. Here are six life science jobs that don’t require industry experience.

The long-awaited review of problematic opioid prescribing is taking longer than observers had hoped.

Amgen announced Tuesday that initial Phase III data of Lumakras in KRAS G12C-mutated NSCLC met the primary endpoint of progression-free survival.

Aria Pharmaceuticals secured six provisional patents to cover the lead drug candidates for its lupus, idiopathic pulmonary fibrosis and chronic kidney disease research programs.

Jounce Therapeutics announced that a Phase II trial assessing a combination treatment for non-small cell lung cancer failed to meet its primary endpoint.

Pfizer signaled its interest in longevity research through a new partnership -and a $500,000 investment - in a decentralized drug development program driven by VitaDAO.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments